Digital crowdsourcing: unleashing its power in rheumatology

Martin Krusche (1),¹ Gerd R Burmester,¹ Johannes Knitza (1)²

Handling editor Josef S Smolen

¹Rheumatology and Clinical Immunology, Charité Universitätsmedizin Berlin, Berlin, Germany ²Department of Internal Medicine 3, Friedrich-Alexander-Universitat Erlangen-Nurnberg, Erlangen, Germany

Correspondence to Dr Martin Krusche.

Rheumatology and Clinical Immunology, Charité Universitäsmedizin Berlin, Berlin D-10117, Germany; martinkrusche@gmx.de

Received 22 April 2020 Revised 5 June 2020 Accepted 5 June 2020 Published Online First 11 June 2020

Check for updates

© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.

To cite: Krusche M, Burmester GR, Knitza J. Ann Rheum Dis 2020;79:1139–1140.

ABSTRACT

The COVID-19 pandemic forces the whole rheumatic and musculoskeletal diseases community to reassemble established treatment and research standards. Digital crowdsourcing is a key tool in this pandemic to create and distil desperately needed clinical evidence and exchange of knowledge for patients and physicians alike. This viewpoint explains the concept of digital crowdsourcing and discusses examples and opportunities in rheumatology. First experiences of digital crowdsourcing in rheumatology show transparent, accessible, accelerated research results empowering patients and rheumatologists.

'Scientia potestas est—Knowledge is power'—This quote, which is linked to Sir Francis Bacon (1561– 1626), is particularly true in medicine. It is the knowledge about the patient and his disease that empowers the physician to provide the best possible care.

An economic perspective refers to the information superiority of the physician in relation to the patient as the theory of 'asymmetric information', leading to a competitive advantage.

Modern medicine naturally leads to a higher level of specialisation and, thus, an increase in asymmetric information. The global COVID-19 pandemic reduced information asymmetry to almost zero and this scenario was entirely new for patients and physicians alike. There are a lack of data concerning COVID-19 in general, the influence of immunosuppression on its course, the interaction with rheumatic diseases and therapeutic use of immunosuppressive drugs (eg, hydroxychloroquine, anti-interleukin (IL)-1 or anti-IL-6 medication).

Digital crowdsourcing promises to clear the mist of current nescience. Crowdsourcing uses the power of many, using the collective wisdom and resources of the crowd, to complete human intelligence tasks.¹ It is not a new concept. Historically, crowdsourcing has often been used in competitions for problem solving. It originated in England in 1714, where the British government proposed £20 000 to anyone who could find a solution for calculating the longitudinal position of a ship.² Digitisation, the internet, global networks and simple and instant data transfer have amplified the idea into a game-changing concept in many scientific fields.

COVID-19 GLOBAL RHEUMATOLOGY ALLIANCE

A significant example of successful digital crowdsourcing in rheumatology is the 'COVID-19 Global Rheumatology Alliance' (https://rheum-covid.org). The international registry collects information pertinent to COVID-19 infection in patients with rheumatic and musculoskeletal diseases (RMD). The registry was set up in record time and is supported by virtually all international professional and patient organisations in the field of rheumatology. Rheumatologists and patients from around the globe are working together to collect data to improve the treatment of patients with RMD with COVID-19. So far, 526 patients have already been enrolled (status: 16 April 2020), and the first important results have been published.³⁻⁶

However, even more remarkable is that the initiative and results are not limited to medical professionals. Crowdsourcing directly involved patients with RMD and results are published constantly, accessible to everyone at any time via the homepage and Twitter feeds. So far, the response from patients was overwhelming. To date, over 9894 patients (status: 18 April 2020) have participated in the survey, actively joining the effort to create and distil clinical knowledge.

OPEN-ACCESS PREPRINT PLATFORMS

Even before the COVID-19 pandemic spread around the globe, open-access digital platforms such as medRxiv and bioRxiv have gained increasing popularity in the scientific community.⁷ These platforms enable researchers to share preprinted data and manuscripts with the scientific community to discuss their research prior to journal publication. Via crowdsourcing, open-peer review can be carried out, allowing for collaboration among researchers and the acceleration of scientific progress. Therefore, these digital platforms improve the openness, accessibility and most of all quality of scientific research.

SOCIAL MEDIA

Social media in particular significantly facilitate crowdsourcing.⁸⁹ Using platforms, like Twitter, Instagram or Facebook, it is easy and instantly possible to get in touch with people from all over the world and different disciplines, to network, discuss topics and issues or to initiate collaborative projects.¹⁰ Twitter journal clubs (ie, @RheumJC¹¹ and @EULAR_JC¹²) are examples of educational digital crowdsourcing that allow the rheumatology community to discuss new scientific work location and time independent.

DATA DONATION AND ARTIFICIAL INTELLIGENCE

Various studies have already shown the great willingness of patients to donate medical data for research purposes to advance scientific progress and thus potentially influence the disease positively for themselves and others.^{13 14}

Especially for rare diseases, digital crowdsourcing has led to significant patient empowerment and



clinical outcome improvements via registries¹⁵ and digital information exchange platforms.¹⁶ Robust datasets can be rapidly crowdfunded to answer complex and frequently asked questions.¹⁷ ¹⁸ These datasets can be used as a basis for artificial intelligence (AI) and machine learning. Moreover, these methods are able to identify new disease subtypes¹⁹ ²⁰ and to predict therapy response²¹ or individual disease progression.²² AI also has the potential to empower the autonomy of patients, for example, by providing individual treatment propositions.²³ New telemedicine approaches such as passive gait analysis²⁴ and remote patient self-monitoring with teleguidance²⁵ and AI-based real-live feedback²⁶ will further encourage the patient empowerment and decrease current information loss in follow-up appointments.

OPPORTUNITIES FOR DIGITAL CROWDSOURCING IN RHEUMATOLOGY

'Knowledge isn't power until it is applied.' Dale Carnegie (1888– 1955, American writer and lecturer)

The COVID-19 pandemic marks a significant turning point in modern medicine. The global healthcare community is confronted with an infection for which almost no prior knowledge or guidelines pre-exist. Frequently, comparisons are made to the Spanish influenza. However, a fundamental difference to the past is the possibility to exchange data and experiences electronically in real time. Via crowdsourcing, the medical community creates a bowl of knowledge that can then be distilled and translated into practical and desperately needed clinical knowledge.

In the long term, COVID pandemic improvisations born from despair could lead to a lasting paradigm shift and information asymmetry cutback also in rheumatology. Digital crowdsourcing and AI should be used to advance global medical collaborations, facilitate patient empowerment and decrease medical barriers. As a rheumatology community, we should embrace the principle of 'connect and engage to target'.

 $\ensuremath{\textbf{Acknowledgements}}$ The authors thank Nikolas Ruffer for proof reading the manuscript.

Contributors MK and JK wrote the manuscript and contributed equally. GRB edited the manuscript and performed medical supervision.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

Patient consent for publication Not required.

Provenance and peer review Not commissioned; externally peer reviewed.

This article is made freely available for use in accordance with BMJ's website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.

ORCID iDs

Martin Krusche http://orcid.org/0000-0002-0582-7790 Johannes Knitza http://orcid.org/0000-0001-9695-0657

REFERENCES

- Créquit P, Mansouri G, Benchoufi M, et al. Mapping of Crowdsourcing in health: systematic review. J Med Internet Res 2018;20:e187.
- 2 Sobel D. Longitude: the true story of a lone genius who solved the greatest scientific problem of his time. New York: Walker Publishing Company, 1995.
- 3 Robinson PC, Yazdany J. The COVID-19 global rheumatology alliance: collecting data in a pandemic. *Nat Rev Rheumatol* 2020;16:293–4.
- 4 Yazdany J, Kim AHJ. Use of hydroxychloroquine and chloroquine during the COVID-19 pandemic: what every clinician should know. *Ann Intern Med* 2020;172:754–5.
- 5 AHJ K, Sparks JA, Liew JW, et al. A rush to judgment? rapid reporting and dissemination of results and its consequences regarding the use of hydroxychloroquine for COVID-19. Annals of Internal Medicine 2020.
- 6 Gianfrancesco MA, Hyrich KL, Gossec L, *et al.* Rheumatic disease and COVID-19: initial data from the COVID-19 global rheumatology alliance provider registries. *Lancet Rheumatol* 2020. doi:10.1016/S2665-9913(20)30095-3. [Epub ahead of print: 16 Apr 2020].
- 7 Callaway E. Will the pandemic permanently alter scientific publishing? *Nature* 2020 http://www.nature.com/articles/d41586-020-01520-4 (cited 2020 Jun 4).
- 8 Seidenwurm D. Social media Crowdsourcing in health care research. *Med Care* 2018;56:1–10.
- 9 Nikiphorou E, Studenic P, Ammitzbøll CG, et al. Social media use among young rheumatologists and basic scientists: results of an international survey by the emerging EULAR network (EMEUNET). Ann Rheum Dis 2017;76:712–5.
- Nikiphorou E, Studenic P, Alunno A, et al. 'Twitterland': a brave new world? Ann Rheum Dis 2018;77:1245–6.
- 11 #RheumaJC. Impact of sustained remission on the risk of serious infection in patients with rheumatoid arthritis.
- 12 Emeunet. EULAR EMEUNET Journal Club. Available: https://emeunet.eular.org/ emeunet_journal_club.cfm
- 13 Skatova A, Goulding J. Psychology of personal data donation. Capraro V, editor. Plos One 2019;14:e0224240.
- 14 Knitza J, Raab C, Lambrecht A, et al. The Urge for Mobile Apps in Rheumatology a German Patient Perspective [abstract]. Arthritis Rheumatol 2019;71.
- 15 Strangfeld A, Richter A. Wie unterstützen Registerdaten die klinische Entscheidungsfindung? Zeitschrift für Rheumatologie 2015;74:119–24.
- 16 van der Vaart R, Repping-Wuts H, Drossaert CHC, et al. Need for online information and support of patients with systemic sclerosis. Arthritis Care Res 2013;65:594–600.
- 17 Dixon WG, Beukenhorst AL, Yimer BB, *et al*. How the weather affects the pain of citizen scientists using a smartphone APP. *NPJ Digit Med* 2019;2:105.
- 18 Hausmann JS, Berna R, Gujral N, et al. Using smartphone Crowdsourcing to redefine normal and febrile temperatures in adults: results from the Feverprints study. J Gen Intern Med 2018;33:2046–7.
- 19 Orange DE, Agius P, DiCarlo EF, et al. Identification of three rheumatoid arthritis disease subtypes by machine learning integration of synovial histologic features and RNA sequencing data. Arthritis Rheumatol 2018;70:690–701.
- 20 SWM E, Olazagasti JM, Goldenberg A, et al. A clinically and biologically based subclassification of the idiopathic inflammatory myopathies using machine learning. ACR Open Rheumatol 2020;2:158–66.
- 21 Guan Y, Zhang H, Quang D, et al. Machine learning to predict Anti–Tumor necrosis factor drug responses of rheumatoid arthritis patients by integrating clinical and genetic markers. Arthritis Rheumatol 2019;71:1987–96.
- 22 Norgeot B, Glicksberg BS, Trupin L, et al. Assessment of a deep learning model based on electronic health record data to forecast clinical outcomes in patients with rheumatoid arthritis. JAMA Network Open 2019;2:e190606.
- 23 Hügle M, Omoumi P, van Laar JM, et al. Applied machine learning and artificial intelligence in rheumatology. *Rheumatol Adv Pract* 2020;4:rkaa005.
- 24 Gossec L, Guyard F, Leroy D, et al. Detection of flares by decrease in physical activity, collected using wearable activity Trackers in rheumatoid arthritis or axial spondyloarthritis: an application of machine learning analyses in rheumatology. *Arthritis Care Res* 2019;71:1336–43.
- 25 Gandrup J, Yazdany J. Using health information technology to support use of patientreported outcomes in rheumatology. *Rheum Dis Clin North Am* 2019;45:257–73.
- 26 Perez MV, Mahaffey KW, Hedlin H, et al. Large-Scale assessment of a Smartwatch to identify atrial fibrillation. N Engl J Med 2019;381:1909–17.